XML 62 R43.htm IDEA: XBRL DOCUMENT
v3.20.2

NOTE 7 – INTANGIBLE ASSETS, NET (Details Narrative) | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2020 USD ($) Number | Jun. 30, 2019 USD ($) | Jun. 30, 2020 USD ($) Number | Jun. 30, 2019 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Amortization of intangible assets | $ | $ 67,748 | $ 48,503 | $ 130,902 | $ 88,948
Approved Hormone Therapy Drug Candidate Patents [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  | 20 years |
OPERA Patent [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Asset Impairment Charges | $ |  |  | $ 78,864 |
Domestic US Patents |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 35 |  | 35 |
Foreign Patents Member |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 35 |  | 35 |
Domestic Patents BIJUVA |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 14 |  | 14 |
Foreign Patents BIJUVA |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 7 |  | 7 |
Domestic Patents NonApproved BIJUVA |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 3 |  | 3 |
Domestic US Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 10 |  | 10 |
Domestic US Utility Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 8 |  | 8 |
Domestic US Design Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 2 |  | 2 |
Foreign Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 16 |  | 16 |
Foreign Utility Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 6 |  | 6 |
Foreign Design Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 10 |  | 10 |
Domestic Utility Patent Topical Cream Candidates [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 1 |  | 1 |
Domestic Utility Patent Transdermal Patch |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 1 |  | 1 |
Foreign Utility Patent Transdermal Patch |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 8 |  | 8 |
Domestic Utility Patent TX009HR |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 3 |  | 3 |
Domestic Patents Progesterone Formulations |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 2 |  | 2 |
Foreign Patents Progesterone Formulations |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 4 |  | 4 |
Domestic Utility Patent Opera |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents | 1 |  | 1 |

X
- Definition Number of issued patents. + References No definition available. + Details
Name: | txmd_NumberOfIssuedPatents
Namespace Prefix: | txmd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_OperaPatentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |